| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
56 |
| Employees |
21,230 |
| Revenues (TTM) (Millions $) |
82 |
| Net Income (TTM) (Millions $) |
-227 |
| Cash Flow (TTM) (Millions $) |
-66 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Zogenix Inc is an American pharmaceutical company that specializes in developing and commercializing innovative therapies for central nervous system disorders. The company is headquartered in Emeryville, California and was founded in 200 Zogenix has operations in the United States, Canada, Europe, and Asia.
The company's focus is on the development and commercialization of drugs for rare and orphan diseases. Its pipeline consists of several drug candidates that target neurological disorders, including Dravet syndrome, Lennox-Gastaut syndrome, and infantile spasms. These disorders are characterized by seizures and other symptoms that affect the quality of life of patients.
Zogenix's flagship product is Fintepla, a drug that was approved by the US FDA (Food and Drug Administration) for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. Fintepla is a Schedule V controlled substance and is available only through a restricted distribution program.
Apart from Fintepla, Zogenix is also developing ZX008 for the treatment of Lennox-Gastaut syndrome, another rare epilepsy disorder. The drug is currently in Phase III clinical trials and has received Orphan Drug Designation from the FDA.
Zogenix has a strong research and development team that collaborates with scientific experts, academic institutions, and industry partners to advance its drug development programs. The company has also established partnerships with other pharmaceutical companies for the development and commercialization of its products.
Zogenix's mission is to improve the lives of patients with central nervous system disorders by developing innovative and effective treatments. The company is committed to ethical and responsible business practices and strives to operate in a sustainable and socially responsible manner.
Company Address: 5959 Horton Street Emeryville 94608 CA
Company Phone Number: 550-8300 Stock Exchange / Ticker: NASDAQ ZGNX
|
%
3.42% 